Exploiting mesoporous silica nanoparticles as versatile drug carriers for several routes of administration

Autor(es)

Sabio, Rafael Miguel ^[1] ; Meneguin, Andreia Bagliotti ^[1] ; dos Santos, Aline Martins ^[1] ; Monteiro, Andreia Sofia ^[2] ; Chorilli, Marlus ^[1]

Afiliação do(s) autor(es)

^[1] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, BR-14800903 Araraquara, SP - Brazil

^[2] Sao Paulo State Univ UNESP, Inst Chem, BR-14800060 Araraquara, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Microporous and Mesoporous Materials; v. 312, JAN 2021.
• Citações Web of Science: 0

Resumo

The exploitation of mesoporous silica nanoparticles (MSNs) as drug delivery systems has grown exponentially due to their remarkable tunable properties, such as high surface area, chemical and physical stability, high loading and release capacities, distinct possibilities of particle and pore structures, as well as good biocompatibility, biodegradability, and easy clearance. However, the main exposure routes that exploit MSNs qualities, namely intravenous, subcutaneous, intramuscular, intratumoral, ophthalmic, pulmonary, nasal, dermal, and oral administrations, have been underreported to date. In addition, a better understanding of these administration routes can contribute to the development of smart MSNs-based nanoplatforms with interesting properties, such as high stability in physiological media, specificity and efficacy in theranostic applications, and further clinical translations. This review highlights the advantages and challenges of the administration routes aforementioned regarding the MSNs as drug delivery systems. It also shows how their properties can influence the interaction with biological media, and consequently, their biocompatibility, biodistribution, and clearance mostly in pre clinical assays, in order to contribute to further MSNs-based nanoplatform clinical translations. (AU)

• Processo FAPESP: 18/25377-3 - Avaliação do potencial de nanopartículas de sílica mesoporosas funcionalizadas com cetuximabe para veiculação de docetaxel no tratamento do câncer de próstata.
• Beneficiário: Rafael Miguel Sábio
• Linha de fomento: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 14/50928-2 - INCT 2014: Nanotecnologia Farmacêutica: uma abordagem transdisciplinar
• Beneficiário: Maria Vitória Lopes Badra Bentley
• Linha de fomento: Auxílio à Pesquisa - Temático